Degradation Products of Fibrinogen and Crosslinked Fibrin—Projected Clinical Applications

Victor J. Marder; Andrei Z. Budzynski

doi:10.1055/s-0038-1647671

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1974; 32(01): 049-056
DOI: 10.1055/s-0038-1647671

Original Article

Schattauer GmbH

Degradation Products of Fibrinogen and Crosslinked Fibrin—Projected Clinical Applications^[*]

Victor J. Marder

¹Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania, 19140

,

Andrei Z. Budzynski

¹Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania, 19140

References
1 Bell W. R, Pitney W. R, Goodwin J. F. 1968; Therapeutic defibrination in the treatment of thrombotic disease. Lancet 01: 490.
2 Blombäck B, Johnson A. J. 1971; Joint report of the subcommittees on nomenclature and on fibrinolysis, thrombolysis, and intravascular coagulation. Thrombosis et Diathesis Haemorrhagica, Suppl 51: 251.
3 Btjdzynski A. Z. 1969; Structure of fibrinogen in relation to its proteolytic degradation products. Postepy Higieny i Medycyny Doswiadczalnej 23: 293.
4 Btjdzynski A. Z, Stahl M, Kopec M, Latallo Z. S, Wegezynowicz Z, Kowalski E. 1967; High molecular weight products of the late stage of fibrinogen proteolysis by plasmin and their structural relation to the fibrinogen molecule. Biochimica et Biophysica Acta 147: 313.
5 Budzynski A. Z, Marder V. J, Shainoff J. R. 1974; Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. Journal of Biological Chemistry 249.
6 Chen R, Doolittle R. F. 1969; Identification of the polypeptide chains involved in the cross-linking of fibrin. Proceedings of the National Academy of Science USA 63: 420.
7 Chen R, Doolittle R. F. 1971; y-y cross-linking sites in human and bovine fibrin. Biochemistry 10: 4486.
8 Dudek G. A, Kloczewiak M, Budzynski A. Z, Latallo Z. S, Kopec M. 1970; Characterization and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin. Biochimica et Biophysica Acta 214: 44.
9 Furlan M, Beck E. A. 1972; Plasmic degradation of human fibrinogen. I. Structural characterization of degradation products. Biochimica et Biophysica Acta 263: 631.
10 Gaffney P. J. 1973; The molecular and functional condition of plasma fibrinogen during thrombolytic therapy with streptokinase (SK). Thrombosis Research 02: 105.
11 Gaffney P. J, Chesterman C. N, Allington M. J. 1974; Plasma fibrinogen and its fragments during streptokinase treatment. British Journal of Haematology 26: 285.
12 Kopec M, Teisseyre E, Dudek-Wojciechowska G, Kloczewiak M, Pankiewicz A, Latallo Z. S. 1973; Studies on the “Double D” fragment from stabilized bovine fibrin. Thrombosis Research 02: 283.
13 Lahiri B, Shainoff J. R. 1973; Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen. Biochimica et Biophysica Acta 303: 161.
14 Loewy A. G. 1968. Enzymatic control of insoluble-fibrin formation. In: Laki K. (Ed.) Fibrinogen. Marcel Dekker, Inc. New York and Edward Arnold (Publishers, Ltd); London: 185.
15 Lorand L, Chenoweth D, Domanik R. A. 1969; Chain pairs in the crosslinking of fibrin. Biochemical and Biophysical Research Communications 37: 219.
16 Marder Y. J. 1968. Immunologic structure of fibrinogen and its plasmin degradation products. Theoretical and clinical considerations. In: Laki K. (Ed.) Fibrinogen, Marcel Dekker, Inc. New York and Edward Arnold (Publishers, Ltd); London: 339.
17 Marder V. J, Budzynski A. Z. 1971; Classification of fibrinogen derivatives. Thrombosis: Risk factors and diagnostic approaches. In: Thrombosis et Diathesis Haemorrhagica Suppl 51: 267.
18 Marder V. J, Shulman N. R, Carroll W. R. 1967; The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage. Tranactions of the Association of the American Physicians 80: 156.
19 Marder V. J, Shulman N. R, Carroll W. R. 1969; High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. Journal of Biological Chemistry 244: 2111.
20 Marder V. J, Budzynski A. Z, James H. L. 1972; High molecular weight derivatives of human fibrinogen produced by plasmin. III. Their N-terminal amino acids and comparison with the “N-terminal disulfide knot.”. Journal of Biological Chemistry 247: 4775.
21 McDonagh R. P, McDonagh Jr. J, Blombäck M, Blombäck B. 1971; Crosslinking of human fibrin: Evidence for intermolecular cross-linking involving a-chains. FEBS Letters 14: 33.
22 McKee P. A, Mattock P, Hill R. L. 1970; Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proceedings of the National Academy of Sciences USA 66: 738.
23 Mills D. A. 1972; Molecular model for the proteolysis of human fibrinogen by plasmin. Biochimica et Biophysica Acta 263: 619.
24 Mills D, Karpatkin S. 1970; Heterogeneity of human fibrinogen: Possible relation to proteolysis by thrombin and plasmin as studied by SDS-polyacrylamide gel electrophoresis. Biochemical and Biophysical Research Communications 40: 206.
25 Mills D, Karpatkin S. 1972; The initial macromolecular derivatives of human fibrinogen produced by plasmin. Biochimica et Biophysica Acta 271: 163.
26 Nossel H. L, Canfield R. E, Butler Jr. V. P. 1973; Plasma fibrinopeptide A concentration as an index of intravascular coagulation. Proceedings of the 4th International Society on Thrombosis and Haemostasis, Vienna 237.
27 Nossel H. L, Younger L. R, Wilner G. D, Procuper T, Canfield R. E, Butler Jr. V. P. 1971; Radioimmunoassay of human fibrinopeptide A. Proceedings of the National Academy of Science USA 68: 2350.
28 Nussenzweig- V, Seligmann M, Pelmont U, Grabar P. 1961; Les produits de degradation du fibrinogène humain par la plasmine. I. Séparation et propriétés physico-chimiques. Annales Institute Pasteur 100: 377.
29 Takagi R, Iwanaga S. 1970; Polypeptide chain involved in the cross-linking of stabilized bovine fibrin. Biochemical and Biophysical Research Communications 38: 129.
30 Takagi R, Iwanaga S. 1970; Polypeptide chain involved in the cross-linking of stabilized bovine fibrin. Biochemical and Biophysical Research Communications 38: 129.
31 Pizzo S. Y, Taylor Jr. L. M, Schwartz M. L, Hill R. L, McKee P. A. 1973; b Subunit structure of fragment D from fibrinogen and cross-linked fibrin. Journal of Biological Chemistry 248: 4584.
32 Robbins K. C. 1944; A study on the conversion of fibrinogen to fibrin. American Journal of Physiology 142: 581.
33 Shainoff J. R, Lahiri B, Bumpus F. M. 1970; Ultracentrifuge studies on the reaction between thrombin and plasminized fibrinogen. Thrombosis et Diathesis Haemorrhagica 39: 203.
34 Sharp A. A, Warren B. A, Paxton A. M, Allington M. J. 1968; Anticoagulant therapy with a purified fraction of malayan pit viper venom. Lancet 01: 493.
35 Takagi R, Iwanaga S. 1970; Polypeptide chain involved in the cross-linking of stabilized bovine fibrin. Biochemical and Biophysical Research Communications 38: 129.

Degradation Products of Fibrinogen and Crosslinked Fibrin—Projected Clinical Applications[*]

Degradation Products of Fibrinogen and Crosslinked Fibrin—Projected Clinical Applications^[*]